Loading...
18 items
2026-07-24
Kaken Pharmaceutical Co., Ltd., ¥ 95.0, Cash Dividend, Sep-29-2026
2026-06-19
R&D Briefing Session
2026-06-19
Kaken Pharmaceutical Co., Ltd., Q2 2026 Earnings Call, Nov 11, 2025
2026-05-30
Kaken Pharmaceutical Co., Ltd. announced that they will report Q1, 2027 results on Aug 07, 2026
2026-05-22
Kaken Pharmaceutical Co., Ltd. proposed cash dividend of JPY 95.00 per share for fiscal year ended March 31, 2026 as compared to JPY 75.00 per share a year ago. Scheduled date of annual general meeting of shareholders: June 26, 2026; Scheduled date of dividend payment commencement: June 29, 2026 .
2026-05-22
Kaken Pharmaceutical Co., Ltd. provided cash dividend guidance for the second quarter and year end of fiscal year ending March 31, 2027. For the second quarter of fiscal year ending March 31, 2027, the company expected dividend of JPY 95.00 per share as compared to JPY 95.00 per share a year ago. For the year end of fiscal year ending March 31, 2027, the company expected dividend of JPY 95.00 per share as compared to JPY 95.00 per share a year ago.
2026-05-22
Kaken Pharmaceutical Co., Ltd. provided consolidated earnings guidance for the fiscal year ending March 31, 2027. For the year, the company expected net sales of JPY 89,900 million; Operating profit of JPY 7,900 million; Profit attributable to owners of the parent of JPY 6,500 million; and Basic earnings per share of JPY 171.65.
2026-05-13
Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 26, 2026.
2026-04-28
Kaken Pharmaceutical Co., Ltd. revised consolidated financial forecast for fiscal year ended March 31, 2026. For the period, the company expects net sales of JPY 76,900 million, operating loss of JPY 900 million and profit attributable to owners of parent company of JPY 2,100 million or basic earnings per share of JPY 55.39 per share compared to previous guidance of net sales of JPY 86,300 million, operating profit of JPY 2,100 million and profit attributable to owners of parent company of JPY 2,300 million or basic earnings per share of JPY 60.74 per share . Initially, the Milestone Payment was expected to be received in the fiscal year ending March 31, 2026 and was incorporated in the consolidated earnings forecast. However, following a milestone achievement has moved back in April 2026, the timing of Milestone Payment has been deferred to the fiscal year ending March 31, 2027.
2026-04-06
Kaken Pharmaceutical Co., Ltd. announced the retirement of Hiroaki Matsumoto as Outside Audit & Supervisory Board Member.
2026-04-01
Kaken Pharmaceutical Co., Ltd., 2026 Earnings Call, May 14, 2026
2026-04-01
Kaken Pharmaceutical Co., Ltd. announced that they will report fiscal year 2026 results on May 13, 2026
2026-03-27
Kaken Pharmaceutical Co., Ltd., Board Meeting, Mar 27, 2026. Agenda: To implement changes to its Directors, Audit & Supervisory Board Members, and Executive Officers.
2026-02-10
Kaken Pharmaceutical Co., Ltd. reported earnings results for the nine months ended December 31, 2025. For the nine months, the company reported sales was JPY 57,617 million compared to JPY 75,990 million a year ago. Net income was JPY 1,398 million compared to JPY 19,175 million a year ago. Basic earnings per share from continuing operations was JPY 36.87 compared to JPY 506.31 a year ago.
2026-01-19
Kaken Pharmaceutical Co., Ltd. expected to report Fiscal Year 2026 results on May 12, 2026. This event was calculated by S&P Global (Created on February 9, 2026).
2025-12-19
Kaken Pharmaceutical Co., Ltd. announced that they will report Q3, 2026 results on Feb 06, 2026
2025-11-11
Kaken Pharmaceutical Co., Ltd., ¥ 95.0, Cash Dividend, Mar-30-2026
2025-11-10
Kaken Pharmaceutical Co., Ltd. expected to report Q3 2026 results on February 5, 2026. This event was calculated by S&P Global (Created on December 10, 2025).
2026Q2 | 2026Q1 | 2025Q4 | 2025Q3 | 2025Q2 | 2025Q1 | 2024Q4 | 2024Q3 | 2024Q2 | 2024Q1 | 2023Q4 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenues | 88,159 | 76,871 | 75,662 | 82,019 | 94,648 | 94,035 | 93,349 | 87,245 | 72,148 | 72,044 | 72,096 |
Pretax Income Excl.Unusual Items | 10,633 | -208 | -3,617 | 2,062 | 18,685 | 21,279 | 26,767 | 24,050 | 9,471 | 9,949 | 5,056 |
Total Assets | 187,414 | 178,217 | 176,440 | 177,279 | 176,341 | 190,422 | 193,422 | 187,123 | 174,777 | 171,623 | 168,337 |
Total Liabilities | 34,533 | 30,599 | 30,632 | 29,477 | 28,895 | 37,788 | 38,165 | 32,718 | 32,258 | 27,869 | 28,202 |
Cash & Cash Equivalents | 52,152 | 44,713 | 36,847 | 45,116 | 43,411 | 54,093 | 63,059 | 67,289 | 51,863 | 50,625 | 51,453 |
Total Common Equity | 152,881 | 147,618 | 145,808 | 147,802 | 147,446 | 152,634 | 155,257 | 154,405 | 142,519 | 143,754 | 140,135 |
Book Value Per Share (BVPS) | 4,037.19 | 3,898.19 | 3,850.39 | 3,903.03 | 3,893.99 | 3,974.44 | 4,099.33 | 4,076.8 | 3,763.41 | 3,796.01 | 3,700.43 |
Net Change in Cash | -19,380 | -26,881 | 4,760 | 13,925 | -8,935 | ||||||
Capital Expenditure | -2,996 | -3,040 | -4,138 | -3,088 | -1,861 |
As of August 07, 2026, Kaken Pharmaceutical published financial results for the second quarter of 2026, with revenues of 30.16B yen and net income of 8.44B yen, reflecting a significant 59.8% surge in revenue, coupled with a substantial increase of about 3028.4% in EPS relative to the corresponding quarter last year.
and it trades at 13.8x times current year's earnings, which is higher than the sector average (P/E 10.9x).
